$26.950
+0.687 (+2.55%)收盤時
BRVE 同業比較
In the context of the broader market, BRVE competes directly with industry leaders such as VCEL and ZYME. With a market capitalization of $1.94B, it holds a significant position in the sector. When comparing efficiency, BRVE's gross margin of N/A stands against VCEL's 72.82% and ZYME's 100.00%. Such benchmarking helps identify whether Braveheart Bio, Inc. is trading at a premium or discount relative to its financial performance.
Braveheart Bio, Inc. 財務表現
The company has shown a year-to-date change of +52.44%, indicating strong market performance since its IPO. However, the P/E ratio is negative at -136.89, reflecting current losses, but this is typical for biotech firms in development stages.
Financials
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。